8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 15, 2026·SEC
Material company update
Apr 13, 2026·SEC
Allogene Therapeutics, Inc.(ALLO)Earnings, Financials & Key Ratios
ALLO•NASDAQ
Price updated Jun 19, 2026
AboutAllogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Show more
- Revenue$0-100.0%
- EBITDA-$195M+25.0%
- Net Income-$191M+25.9%
- EPS (Diluted)-0.87+34.1%
- ROE-53.42%+3.1%
ALLO Key Insights
Allogene Therapeutics, Inc. (ALLO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 13.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ALLO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALLO Price & Volume
Allogene Therapeutics, Inc. (ALLO) stock price & volume — 10-year historical chart
Loading chart...
ALLO Growth Metrics
Allogene Therapeutics, Inc. (ALLO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM31.14%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM37.4%
Return on Capital
10 Years-34.94%
5 Years-39.5%
3 Years-47.57%
Last Year-46.16%
ALLO Recent Earnings
Allogene Therapeutics, Inc. (ALLO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 5/12 qtrs (100%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.18+5.3%
$0.19
Rev
—
$2,222
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.17+32.0%
$0.25
Rev
—
$2,500
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.19+17.4%
$0.23
Rev
—
$1,820
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.23+17.9%
$0.28
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.18vs $0.19+5.3% | —vs $2,222 |
| Q2 2026 | Mar 12, 2026 | $0.17vs $0.25+32.0% | —vs $2,500 |
| Q4 2025 | Nov 6, 2025 | $0.19vs $0.23+17.4% | —vs $1,820 |
| Q3 2025 | Aug 13, 2025 | $0.23vs $0.28+17.9% | — |
Based on last 12 quarters of dataView full earnings history →
ALLO Peer Comparison
Allogene Therapeutics, Inc. (ALLO) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 CELH | 7.87B | 30.80 | 123.20 | 85.54% | 5.85% | 7.51% | 0.23 | |
 CABA | 463.08M | 2.84 | -1.73 | -131.58% | 0.24 | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 |
Compare ALLO vs Peers
Allogene Therapeutics, Inc. (ALLO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALLO Income Statement
Allogene Therapeutics, Inc. (ALLO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 114.09M | 156K | 95K | 22K | 0 | 0 |
Revenue Growth % | - | - | - | - | - | -99.86% | -39.1% | -76.84% | -100% | - |
Cost of Goods Sold | 0 | 0 | 5.03M | 11.54M | 0 | 14.29M | 0 | 0 | 12.36M | 37.09M |
COGS % of Revenue | - | - | - | - | - | 9163.46% | - | - | - | - |
Gross Profit | 0▲ 0% | -1.5M▲ 0% | -5.03M▼ 235.1% | -11.54M▼ 129.6% | 114.09M▲ 1088.6% | -14.14M▼ 112.4% | 95K▲ 100.7% | 22K▼ 76.8% | -12.36M▼ 56277.3% | -37.09M▲ 0% |
Gross Margin % | - | - | - | - | 100% | -9063.46% | 100% | 100% | - | - |
Gross Profit Growth % | - | - | -235.13% | -129.58% | 1088.55% | -112.39% | 100.67% | -76.84% | -56277.27% | - |
Operating Expenses | 2K | 192.84M | 202.01M | 246.7M | 294.28M | 321.4M | 327.83M | 273.22M | 194.57M | 153.13M |
OpEx % of Revenue | - | - | - | - | 257.94% | 206023.72% | 345086.32% | 1241913.64% | - | - |
Selling, General & Admin | 2K | 40.98M | 57.47M | 65.26M | 74.11M | 79.31M | 71.67M | 65.2M | 56.78M | 55.88M |
SG&A % of Revenue | - | - | - | - | 64.95% | 50836.54% | 75445.26% | 296386.36% | - | - |
Research & Development | 0 | 151.86M | 144.53M | 192.99M | 220.18M | 256.39M | 242.91M | 192.3M | 150.15M | 129.09M |
R&D % of Revenue | - | - | - | - | 192.99% | 164350.64% | 255698.95% | 874086.36% | - | - |
Other Operating Expenses | 0 | 0 | 0 | -11.54M | 0 | -14.29M | 13.24M | 15.72M | -12.36M | -1000K |
Operating Income | -2K▲ 0% | -192.84M▼ 9642000.0% | -202.01M▼ 4.8% | -258.24M▼ 27.8% | -180.19M▲ 30.2% | -335.54M▼ 86.2% | -327.74M▲ 2.3% | -273.2M▲ 16.6% | -206.93M▲ 24.3% | -190.22M▲ 0% |
Operating Margin % | - | - | - | - | -157.94% | -215087.18% | -344986.32% | -1241813.64% | - | - |
Operating Income Growth % | - | -9642000% | -4.75% | -27.84% | 30.22% | -86.21% | 2.32% | 16.64% | 24.26% | - |
EBITDA | 22K | -191.34M | -196.98M | -246.7M | -169.74M | -321.24M | -313.54M | -259.56M | -194.57M | -178.09M |
EBITDA Margin % | - | - | - | - | -148.78% | -205923.72% | -330040% | -1179818.18% | - | - |
EBITDA Growth % | - | -869836.36% | -2.95% | -25.24% | 31.2% | -89.26% | 2.4% | 17.22% | 25.04% | 30.35% |
D&A (Non-Cash Add-back) | 24K | 1.5M | 5.03M | 11.54M | 10.45M | 14.29M | 14.2M | 13.64M | 12.36M | 12.13M |
EBIT | -2K | -208.26M | -184.93M | -250.22M | -180.19M | -335.54M | -327.26M | -256.97M | -206.93M | -180.23M |
Net Interest Income | 0 | 2.43M | 17.35M | 9.16M | 1.71M | 4.57M | 18.31M | 19.97M | 18.21M | 12.2M |
Interest Income | 0 | 5.79M | 17.35M | 9.16M | 1.71M | 4.57M | 18.31M | 20.15M | 19.29M | 13.42M |
Interest Expense | 0 | 3.36M | 0 | 0 | 0 | 0 | 0 | 181K | 1.07M | 1.23M |
Other Income/Expense | 0 | -18.78M | 17.08M | 8.02M | -1.86M | -4.88M | 472K | 16.05M | 16.05M | 16.46M |
Pretax Income | -24K▲ 0% | -211.62M▼ 881658.3% | -184.93M▲ 12.6% | -250.22M▼ 35.3% | -182.05M▲ 27.2% | -340.41M▼ 87.0% | -327.26M▲ 3.9% | -257.15M▲ 21.4% | -190.89M▲ 25.8% | -173.76M▲ 0% |
Pretax Margin % | - | - | - | - | -159.57% | -218214.1% | -344489.47% | -1168850% | - | - |
Income Tax | -24K | -117K | -331K | 0 | 0 | 0 | 0 | 443K | 0 | 0 |
Effective Tax Rate % | 100% | 0.06% | 0.18% | 0% | 0% | 0% | 0% | -0.17% | 0% | 0% |
Net Income | -2K▲ 0% | -211.5M▼ 10575150.0% | -184.59M▲ 12.7% | -250.22M▼ 35.6% | -182.05M▲ 27.2% | -340.41M▼ 87.0% | -327.26M▲ 3.9% | -257.59M▲ 21.3% | -190.89M▲ 25.9% | -173.76M▲ 0% |
Net Margin % | - | - | - | - | -159.57% | -218214.1% | -344489.47% | -1170863.64% | - | - |
Net Income Growth % | - | -10575150% | 12.72% | -35.55% | 27.24% | -86.99% | 3.86% | 21.29% | 25.9% | 31.14% |
Net Income (Continuing) | -2K | -211.5M | -184.59M | -250.22M | -182.05M | -340.41M | -327.26M | -257.59M | -190.89M | -173.76M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.00▲ 0% | -2.36▲ 0% | -1.83▲ 22.5% | -2.08▼ 13.7% | -1.34▲ 35.6% | -2.38▼ 77.6% | -2.09▲ 12.2% | -1.32▲ 36.8% | -0.87▲ 34.1% | -0.72▲ 0% |
EPS Growth % | - | - | 22.46% | -13.66% | 35.58% | -77.61% | 12.18% | 36.84% | 34.09% | 37.4% |
EPS (Basic) | 0.00 | -2.36 | -1.83 | -2.08 | -1.34 | -2.38 | -2.09 | -1.32 | -0.87 | - |
Diluted Shares Outstanding | 44.01M | 89.69M | 101.06M | 120.37M | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M | 240.29M |
Basic Shares Outstanding | 44.01M | 89.69M | 101.06M | 120.37M | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M | 240.29M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ALLO Balance Sheet
Allogene Therapeutics, Inc. (ALLO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 0 | 467.98M | 544.58M | 845.13M | 471.32M | 528.82M | 459.12M | 303.39M | 257.75M | 273.29M |
Cash & Short-Term Investments | 0 | 721.35M | 530.53M | 827.91M | 457.3M | 517.32M | 448.7M | 292.48M | 250.21M | 266.89M |
Cash Only | 0 | 721.35M | 175.13M | 183.35M | 173.31M | 61.9M | 83.16M | 75.22M | 51.69M | 30.31M |
Short-Term Investments | 0 | 0 | 355.41M | 644.56M | 283.99M | 455.42M | 365.54M | 217.26M | 198.52M | 236.58M |
Accounts Receivable | 0 | 3.11M | 2.4M | 0 | 0 | 0 | 1.7M | 1.9M | 1.5M | 1.3M |
Days Sales Outstanding | - | - | - | - | - | - | 6.53K | 31.52K | - | - |
Inventory | 0 | -261.97M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | -2.4M | 0 | 0 | 11.5M | 0 | 9.01M | 6.04M | 5.11M |
Total Non-Current Assets | 0 | 305.87M | 173.23M | 382.7M | 579.5M | 292.75M | 183.72M | 245.32M | 158.16M | 122.67M |
Property, Plant & Equipment | 0 | 41.61M | 100.94M | 160.13M | 181.02M | 196.43M | 163.18M | 131.26M | 112.73M | 108.84M |
Fixed Asset Turnover | - | - | - | - | 0.63x | 0.00x | 0.00x | 0.00x | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 754K | 151K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 261.97M | 63.21M | 207.95M | 382.38M | 76.47M | 3.65M | 80.67M | 8.04M | 83.08M |
Other Non-Current Assets | 0 | 1.54M | 8.92M | 14.62M | 16.11M | 19.86M | 16.9M | 33.39M | 37.39M | 3.53M |
Total Assets | 0▲ 0% | 773.86M▲ 0% | 717.8M▼ 7.2% | 1.23B▲ 71.1% | 1.05B▼ 14.4% | 821.58M▼ 21.8% | 642.84M▼ 21.8% | 548.71M▼ 14.6% | 415.9M▼ 24.2% | 395.96M▲ 0% |
Asset Turnover | - | - | - | - | 0.11x | 0.00x | 0.00x | 0.00x | - | 0.00x |
Asset Growth % | - | - | -7.24% | 71.05% | -14.42% | -21.82% | -21.76% | -14.64% | -24.2% | -98.86% |
Total Current Liabilities | 2K | 29.46M | 33.08M | 94.32M | 47.91M | 53.73M | 37.08M | 35.52M | 32.51M | 28.33M |
Accounts Payable | 0 | 12.34M | 9.25M | 10.39M | 10.26M | 13.89M | 5.9M | 5.39M | 4.27M | 4.93M |
Days Payables Outstanding | - | - | 671.62 | 328.6 | - | 354.66 | - | - | 126.11 | 43.68 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.42M |
Deferred Revenue (Current) | 0 | 0 | 0 | 38.99M | 156K | 95K | 86K | 0 | 0 | 0 |
Other Current Liabilities | 0 | 5.2M | 12.4M | 12.97M | 16.13M | 17.93M | 11.66M | 12.15M | 28.24M | 14.98M |
Current Ratio | - | 15.89x | 16.46x | 8.96x | 9.84x | 9.84x | 12.38x | 8.54x | 7.93x | 9.65x |
Quick Ratio | - | 24.78x | 16.46x | 8.96x | 9.84x | 9.84x | 12.38x | 8.54x | 7.93x | 9.65x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 41.23M | 55.7M | 53.89M | 77.72M | 100.97M | 93.53M | 91.01M | 90.85M | 88.75M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 34.46M | 51.35M | 50.81M | 69.93M | 95.12M | 88.35M | 83.25M | 75.05M | 304.05M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 6.78M | 4.35M | 3.08M | 7.79M | 5.85M | 5.18M | 7.76M | 15.8M | 16.12M |
Total Liabilities | 2K | 70.69M | 88.78M | 148.21M | 125.63M | 154.7M | 130.6M | 126.53M | 123.36M | 117.08M |
Total Debt | 0 | 34.46M | 53.03M | 53.78M | 73.13M | 101.12M | 95.12M | 90.76M | 75.05M | 81.05M |
Net Debt | 0 | -686.89M | -122.1M | -129.57M | -100.19M | 39.22M | 11.97M | 15.54M | 23.36M | 50.74M |
Debt / Equity | - | 0.05x | 0.08x | 0.05x | 0.08x | 0.15x | 0.19x | 0.21x | 0.26x | 0.29x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.46x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.28x |
Interest Coverage | - | -62.02x | - | - | - | - | - | -1419.70x | -192.50x | -147.12x |
Total Equity | -2K▲ 0% | 703.16M▲ 35158300.0% | 629.02M▼ 10.5% | 1.08B▲ 71.6% | 925.2M▼ 14.3% | 666.88M▼ 27.9% | 512.23M▼ 23.2% | 422.18M▼ 17.6% | 292.54M▼ 30.7% | 278.88M▲ 0% |
Equity Growth % | - | 35158300% | -10.54% | 71.63% | -14.3% | -27.92% | -23.19% | -17.58% | -30.71% | -123.45% |
Book Value per Share | -0.00 | 7.84 | 6.22 | 8.97 | 6.81 | 4.66 | 3.26 | 2.17 | 1.33 | 1.16 |
Total Shareholders' Equity | -2K | 703.16M | 629.02M | 1.08B | 925.2M | 666.88M | 512.23M | 422.18M | 292.54M | 278.88M |
Common Stock | 26K | 121K | 124K | 140K | 142K | 144K | 169K | 212K | 229K | 245K |
Retained Earnings | -23K | -211.53M | -396.12M | -646.34M | -894.55M | -1.23B | -1.56B | -1.82B | -2.01B | -2.05B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -5K | 306K | 1.15M | 268K | -2.57M | -9.93M | -955K | -89K | 269K | -183K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALLO Cash Flow Statement
Allogene Therapeutics, Inc. (ALLO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 0 | -44.65M | -137.35M | -115.09M | -184.81M | -220.52M | -237.73M | -200.3M | -149.25M | -109.23M |
Operating CF Margin % | - | - | - | - | -161.99% | -141358.33% | -250245.26% | -910454.55% | - | - |
Operating CF Growth % | - | - | -207.59% | 16.2% | -60.58% | -19.32% | -7.81% | 15.75% | 25.49% | 171.72% |
Net Income | -24K | -211.5M | -184.59M | -250.22M | -257M | -332.63M | -327.26M | -257.59M | -190.89M | -173.76M |
Depreciation & Amortization | 0 | 1.5M | 5.03M | 7.59M | 10.45M | 14.29M | 14.2M | 13.64M | 12.36M | 12.13M |
Stock-Based Compensation | 0 | 18.57M | 46.06M | 65.26M | 80.82M | 83.6M | 65.95M | 51.74M | 37.64M | 25.47M |
Deferred Taxes | 0 | -117K | -331K | 4.4M | 10.4M | 8.08M | 0 | 443K | 0 | 0 |
Other Non-Cash Items | 0 | 134.81M | 3.36M | 3.96M | 2.61M | 2.43M | 24.69M | 16.26M | 2.52M | 11.15M |
Working Capital Changes | 24K | 12.1M | -6.88M | 53.92M | -32.09M | 3.71M | -15.3M | -24.8M | -10.88M | 15.79M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 8.8M | -985K | 615K | -767K | 4.87M | -7.5M | -503K | -1.23M | -232K |
Cash from Investing | 0 | -632.8M | 164.08M | -505.12M | 163.66M | 106.16M | 163.29M | 75.69M | 95.56M | 59.8M |
Capital Expenditures | 0 | -3.23M | -50.79M | -65.96M | -21.45M | -5.19M | -1.52M | -694K | -386K | -296K |
CapEx % of Revenue | - | - | - | - | 18.8% | 3327.56% | 1595.79% | 3154.55% | - | - |
Acquisitions | 0 | 0 | -5.08M | 439.17M | -17.71M | -111.35M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -2.1M | 0 | -439.17M | 0 | 111.35M | 0 | 0 | 0 | 0 |
Cash from Financing | 0 | 771.18M | 58.96M | 633.59M | 11.96M | 2.95M | 95.69M | 116.67M | 30.16M | 37.29M |
Debt Issued (Net) | 0 | 116.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 54.22M | 621.93M | 11.96M | 2.95M | 91.11M | 114.39M | 23.25M | 33.73M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 654.34M | 4.74M | 11.66M | 0 | 0 | 4.58M | 2.28M | 6.91M | 3.56M |
Net Change in Cash | 0▲ 0% | 93.73M▲ 0% | 85.69M▼ 8.6% | 13.38M▼ 84.4% | -9.19M▼ 168.7% | -111.41M▼ 1111.8% | 21.25M▲ 119.1% | -7.94M▼ 137.3% | -23.53M▼ 196.5% | -12.15M▲ 0% |
Free Cash Flow | 0▲ 0% | -47.89M▲ 0% | -188.14M▼ 292.9% | -181.05M▲ 3.8% | -206.26M▼ 13.9% | -225.71M▼ 9.4% | -239.25M▼ 6.0% | -200.99M▲ 16.0% | -149.63M▲ 25.6% | -109.53M▲ 0% |
FCF Margin % | - | - | - | - | -180.79% | -144685.9% | -251841.05% | -913609.09% | - | - |
FCF Growth % | - | - | -292.89% | 3.77% | -13.92% | -9.43% | -6% | 15.99% | 25.55% | 44.72% |
FCF per Share | - | -0.53 | -1.86 | -1.50 | -1.52 | -1.58 | -1.52 | -1.03 | -0.68 | -0.46 |
FCF Conversion (FCF/Net Income) | - | 0.21x | 0.74x | 0.46x | 1.02x | 0.65x | 0.73x | 0.78x | 0.78x | 0.63x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALLO Key Ratios
Allogene Therapeutics, Inc. (ALLO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -60.16% | -27.71% | -29.29% | -18.16% | -42.76% | -55.51% | -55.13% | -53.42% | -56.45% |
Return on Invested Capital (ROIC) | -1778.11% | -57.92% | -26.59% | -15.23% | -32.87% | -39.96% | -42.6% | -41.19% | -41.12% |
Gross Margin | - | - | - | 100% | -9063.46% | 100% | 100% | - | - |
Net Margin | - | - | - | -159.57% | -218214.1% | -344489.47% | -1170863.64% | - | - |
Debt / Equity | 0.05x | 0.08x | 0.05x | 0.08x | 0.15x | 0.19x | 0.21x | 0.26x | 0.29x |
Interest Coverage | -62.02x | - | - | - | - | - | -1419.70x | -192.50x | -147.12x |
FCF Conversion | 0.21x | 0.74x | 0.46x | 1.02x | 0.65x | 0.73x | 0.78x | 0.78x | 0.63x |
Revenue Growth | - | - | - | - | -99.86% | -39.1% | -76.84% | -100% | - |
Related:ALLO Dividend History·ALLO Revenue History·ALLO Price History·ALLO P/E History·ALLO Financial Ratios·ALLO Institutional Holders
ALLO SEC Filings & Documents
Allogene Therapeutics, Inc. (ALLO) SEC filings — annual & quarterly reports (10-K, 10-Q)
ALLO Frequently Asked Questions
Allogene Therapeutics, Inc. (ALLO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Allogene Therapeutics, Inc. (ALLO) saw revenue decline by 100.0% over the past year.
Allogene Therapeutics, Inc. (ALLO) reported a net loss of $173.8M for fiscal year 2025.
Dividend & Returns
Allogene Therapeutics, Inc. (ALLO) has a return on equity (ROE) of -53.4%. Negative ROE indicates the company is unprofitable.
Allogene Therapeutics, Inc. (ALLO) had negative free cash flow of $109.5M in fiscal year 2025, likely due to heavy capital investments.